No Data
No Data
Orchard Software Partners With Luxor Scientific to Expand Testing Services
CARMEL, Ind., May 8, 2024 /PRNewswire/ -- Orchard Software is pleased to announce its collaborative test-expansion partnership with Luxor Scientific Medical Laboratories. Luxor Scientific has grown r
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today
Orchard Software Announces New Electronic Support for Antimicrobial Stewardship
CARMEL, Ind., April 4, 2024 /PRNewswire/ -- Today, Orchard Software announced the availability of Antimicrobial Use and Resistance (AUR) reporting to the National Healthcare Safety Network (NHSN), wh
Orchard Therapeutics Announces Launch Plans For Lenmeldy - Quick Facts
Orchard Therapeutics Receives FDA Approval of Lenmeldy (Atidarsagene Autotemcel), the Only Therapy for Eligible Children With Early-onset Metachromatic Leukodystrophy in the U.S.
Orchard Therapeutics today announced the U.S. Food and Drug Administration (FDA) has approved Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD).
ORI Capital Raises $260 Million for Second Life Sciences Fund
- Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally ORI Capital today announced the final close of its second fund, ORI Fund II
SpyderCall : Good stuff. As usual.